Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,539 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial.
Furuta S, Nakagomi D, Kobayashi Y, Hiraguri M, Sugiyama T, Amano K, Umibe T, Kono H, Kurasawa K, Kita Y, Matsumura R, Kaneko Y, Ninagawa K, Hiromura K, Kagami SI, Inaba Y, Hanaoka H, Ikeda K, Nakajima H; LoVAS Collaborators. Furuta S, et al. Among authors: kobayashi y. JAMA. 2021 Jun 1;325(21):2178-2187. doi: 10.1001/jama.2021.6615. JAMA. 2021. PMID: 34061144 Free PMC article. Clinical Trial.
B and T lymphocyte attenuator inhibits LPS-induced endotoxic shock by suppressing Toll-like receptor 4 signaling in innate immune cells.
Kobayashi Y, Iwata A, Suzuki K, Suto A, Kawashima S, Saito Y, Owada T, Kobayashi M, Watanabe N, Nakajima H. Kobayashi Y, et al. Among authors: kobayashi m. Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5121-6. doi: 10.1073/pnas.1222093110. Epub 2013 Mar 11. Proc Natl Acad Sci U S A. 2013. PMID: 23479601 Free PMC article.
Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial.
Furuta S, Sugiyama T, Umibe T, Kaneko Y, Amano K, Kurasawa K, Nakagomi D, Hiraguri M, Hanaoka H, Sato Y, Ikeda K, Nakajima H; LoVAS Trial study investigators. Furuta S, et al. BMJ Open. 2017 Dec 14;7(12):e018748. doi: 10.1136/bmjopen-2017-018748. BMJ Open. 2017. PMID: 29247107 Free PMC article. Clinical Trial.
Latent class analysis of 216 patients with adult-onset Still's disease.
Sugiyama T, Furuta S, Hiraguri M, Ikeda K, Inaba Y, Kagami SI, Kita Y, Kobayashi K, Kobayashi Y, Kurasawa K, Nakagomi D, Nawata Y, Kawasaki Y, Shiko Y, Sugiyama T, Nakajima H. Sugiyama T, et al. Among authors: kobayashi y, kobayashi k. Arthritis Res Ther. 2022 Jan 3;24(1):7. doi: 10.1186/s13075-021-02708-3. Arthritis Res Ther. 2022. PMID: 34980244 Free PMC article.
Prognosis of spontaneous pneumomediastinum occurring in dermatomyositis or polymyositis patients with interstitial lung disease according to antimelanoma differentiation-associated gene 5 antibody status: a retrospective cohort study.
Abe K, Furuta S, Kobayashi Y, Sugiyama T, Kagami SI, Nakagomi D, Iwamoto T, Ikeda K, Nakajima H. Abe K, et al. Among authors: kobayashi y. RMD Open. 2023 Feb;9(1):e002770. doi: 10.1136/rmdopen-2022-002770. RMD Open. 2023. PMID: 36759007 Free PMC article.
10,539 results
You have reached the last available page of results. Please see the User Guide for more information.